Patients used in this study
| Characteristic . | No cGVHD, n = 13 . | Active cGVHD, n = 17 . | P . |
|---|---|---|---|
| Median age (range), y | 51 (29-73) | 49 (22-69) | .57 |
| Sex, females, no. (%) | 5 (42) | 5 (29) | .71 |
| Median time after transplant (range), mo | 43 (12-81) | 45 (12-114) | .71 |
| Conditioning regimen (%) | .71 | ||
| Myeloablative | 6 (46) | 10 (59) | |
| Nonmyeloablative | 7 (54) | 7 (41) | |
| Source of graft (%) | 1 | ||
| Peripheral blood | 10 (77) | 13 (76) | |
| Bone marrow | 3 (23) | 4 (24) | |
| HLA matching (%) | .72 | ||
| Matched, unrelated | 7 (54) | 8 (47) | |
| Matched, related | 6 (46) | 7 (41) | |
| Mismatched | 0 (0) | 2 (12) | |
| Immunosuppressive treatment (%) | <.0001 | ||
| Prednisone <0.5 mg/kg | 1 (8) | 10 (59) | |
| MMF | 0 (0) | 1 (6) | |
| Tacrolimus | 1 (8) | 7 (41) | |
| Rapamycin | 0 (0) | 1 (6) | |
| Initial disease (%) | .41 | ||
| AML/AML from MDS | 4 (31) | 5 (29) | |
| ALL | 0 (0) | 2 (12) | |
| CML | 0 (0) | 1 (6) | |
| CLL | 2 (15) | 1 (6) | |
| MDS | 3 (23) | 3 (18) | |
| NHL | 1 (8) | 2 (12) | |
| MM | 1 (8) | 0 (0) | |
| AA | 2 (15) | 0 (0) | |
| Other | 0 (0) | 3 (18) |
| Characteristic . | No cGVHD, n = 13 . | Active cGVHD, n = 17 . | P . |
|---|---|---|---|
| Median age (range), y | 51 (29-73) | 49 (22-69) | .57 |
| Sex, females, no. (%) | 5 (42) | 5 (29) | .71 |
| Median time after transplant (range), mo | 43 (12-81) | 45 (12-114) | .71 |
| Conditioning regimen (%) | .71 | ||
| Myeloablative | 6 (46) | 10 (59) | |
| Nonmyeloablative | 7 (54) | 7 (41) | |
| Source of graft (%) | 1 | ||
| Peripheral blood | 10 (77) | 13 (76) | |
| Bone marrow | 3 (23) | 4 (24) | |
| HLA matching (%) | .72 | ||
| Matched, unrelated | 7 (54) | 8 (47) | |
| Matched, related | 6 (46) | 7 (41) | |
| Mismatched | 0 (0) | 2 (12) | |
| Immunosuppressive treatment (%) | <.0001 | ||
| Prednisone <0.5 mg/kg | 1 (8) | 10 (59) | |
| MMF | 0 (0) | 1 (6) | |
| Tacrolimus | 1 (8) | 7 (41) | |
| Rapamycin | 0 (0) | 1 (6) | |
| Initial disease (%) | .41 | ||
| AML/AML from MDS | 4 (31) | 5 (29) | |
| ALL | 0 (0) | 2 (12) | |
| CML | 0 (0) | 1 (6) | |
| CLL | 2 (15) | 1 (6) | |
| MDS | 3 (23) | 3 (18) | |
| NHL | 1 (8) | 2 (12) | |
| MM | 1 (8) | 0 (0) | |
| AA | 2 (15) | 0 (0) | |
| Other | 0 (0) | 3 (18) |
All patients were consented, all samples were obtained, and all studies were approved under the institutional review board protocols of Duke University, the National Institutes of Health, and the Dana-Farber Cancer Institute. Statistical comparisons between groups were performed using the Fisher exact test.
AA, aplastic anemia; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; MDS, myelodysplastic syndrome; MM, multiple myeloma; MMF, mycophenolate mofetil.